Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009955
Filing Date
2025-05-13
Accepted
2025-05-13 16:20:32
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 883553
2 EX-31.1 ex31-1.htm EX-31.1 18835
3 EX-31.2 ex31-2.htm EX-31.2 18912
4 EX-32.1 ex32-1.htm EX-32.1 8565
5 EX-32.2 ex32-2.htm EX-32.2 8430
  Complete submission text file 0001641172-25-009955.txt   5055883

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ensc-20250331.xsd EX-101.SCH 40515
7 XBRL CALCULATION FILE ensc-20250331_cal.xml EX-101.CAL 44912
8 XBRL DEFINITION FILE ensc-20250331_def.xml EX-101.DEF 172308
9 XBRL LABEL FILE ensc-20250331_lab.xml EX-101.LAB 336743
10 XBRL PRESENTATION FILE ensc-20250331_pre.xml EX-101.PRE 271445
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 698261
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38306 | Film No.: 25940442
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)